MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study

Pediatric Eye Disease Investigator Group (PEDIG)

doi:10.1001/jamaophthalmol.2021.0349

MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study

Pediatric Eye Disease Investigator Group (PEDIG)

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	583-585
Number of pages	3
Journal	JAMA Ophthalmology
Volume	139
Issue number	5
DOIs	https://doi.org/10.1001/jamaophthalmol.2021.0349
State	Published - May 2021

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1001/jamaophthalmol.2021.0349

Cite this

@article{c586e27f07c24174b4f0511826e060ad,

title = "MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study",

author = "{Pediatric Eye Disease Investigator Group (PEDIG)} and Chen, {John J.} and Pineles, {Stacy L.} and Repka, {Michael X.} and Pittock, {Sean J.} and Henderson, {Robert J.} and Liu, {Grant T.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Pittock reports grants from Grifols and the Autoimmune Encephalitis Alliance; honoraria and travel expenses from MedImmune, Inc and Alexion Pharmaceuticals, Inc; consulting fees from Astellas; personal fees from Genentech Sage Therapeutics, and Prime Therapeutics, UCB, Inc, and Hoffman/LaRoche AG; and consulting compensation from Euroimmun outside the submitted work; and has patents 8,889,102 for neuromyelitis optica autoantibodies as a marker for neoplasia and 9,891,219B2 for methods for treating neuromyelitis optica by administration of eculizumab to an individual that is aquaporin-4-IgG autoantibody positive; and pending patents for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. No other disclosures were reported. Funding/Support: This research was supported by grants EY011751, EY018810, and EY023198 from the National Eye Institute. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2021",

month = may,

doi = "10.1001/jamaophthalmol.2021.0349",

language = "English (US)",

volume = "139",

pages = "583--585",

journal = "JAMA Ophthalmology",

issn = "2168-6165",

publisher = "American Medical Association",

number = "5",

}

TY - JOUR

T1 - MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study

AU - Pediatric Eye Disease Investigator Group (PEDIG)

AU - Chen, John J.

AU - Pineles, Stacy L.

AU - Repka, Michael X.

AU - Pittock, Sean J.

AU - Henderson, Robert J.

AU - Liu, Grant T.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Pittock reports grants from Grifols and the Autoimmune Encephalitis Alliance; honoraria and travel expenses from MedImmune, Inc and Alexion Pharmaceuticals, Inc; consulting fees from Astellas; personal fees from Genentech Sage Therapeutics, and Prime Therapeutics, UCB, Inc, and Hoffman/LaRoche AG; and consulting compensation from Euroimmun outside the submitted work; and has patents 8,889,102 for neuromyelitis optica autoantibodies as a marker for neoplasia and 9,891,219B2 for methods for treating neuromyelitis optica by administration of eculizumab to an individual that is aquaporin-4-IgG autoantibody positive; and pending patents for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. No other disclosures were reported. Funding/Support: This research was supported by grants EY011751, EY018810, and EY023198 from the National Eye Institute. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2021/5

Y1 - 2021/5

UR - http://www.scopus.com/inward/record.url?scp=85103354023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103354023&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2021.0349

DO - 10.1001/jamaophthalmol.2021.0349

M3 - Letter

C2 - 33764379

AN - SCOPUS:85103354023

SN - 2168-6165

VL - 139

SP - 583

EP - 585

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

IS - 5

ER -

MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this